drugset / Trial / NCT02848170

Study of CS-3150 Compared to Olmesartan in Patients With Essential Hypertension

NCT02848170

Completed 40 enrolled Daiichi Sankyo
RandomizedCrossoverOpen-labelTreatment

Summary

Phase 3 study to examine the relation between antihypertensive effect and baseline factors exploratively, compared to olmesartan medoxomil in patients with essential hypertension.

Timeline

Start
2016-08
Primary completion
2017-04
Completion
2017-04

Drugs

EvaluationDrugModalityDoseRoute
Subject CS-3150 Unknown 2.5 mg Oral
Comparator Olmesartan medoxomil Unknown 10 mg Oral